Publications by authors named "Y Rukazenkov"
Background: Distant metastases in non-small-cell lung cancer (NSCLC) are a poor prognostic factor that negatively impact quality of life. The central nervous system (CNS) is a common site of distant progression in epidermal growth factor receptor-mutated (EGFRm) NSCLC. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor recommended for advanced EGFRm NSCLC and as adjuvant treatment for resected EGFRm NSCLC.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib is a targeted therapy for EGFR-mutated non-small cell lung cancer that was evaluated for its effectiveness and safety based on plasma concentration levels in a large clinical study involving 1,689 patients.* -
- The analysis revealed that while osimertinib was more effective than other treatments regardless of dosage, there was no significant increase in efficacy with higher drug exposure, but a potential rise in side effects like interstitial lung disease, rash, and diarrhea.* -
- Overall, the findings suggest that higher doses of osimertinib (≥80 mg) may not provide additional benefits in treatment efficacy but could lead to more severe adverse effects, particularly in certain patient subgroups.*
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.
J Thorac Oncol
November 2024
Introduction: EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib targets and inhibits the epidermal growth factor receptor (EGFR) in cancer cells, leading to cell death and reduced tumors, making it a key treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
- The ADAURA study compared the effects of osimertinib to a placebo in patients with surgically removed early-stage (IB-IIIA) EGFR-mutated NSCLC, showing that those on osimertinib had longer disease-free survival.
- Recent results reveal that osimertinib significantly improves overall survival, with a 51% lower risk of death for patients treated with it compared to the placebo group.
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
J Mol Diagn
January 2024
Comprehensive genotyping is necessary to identify therapy options for patients with advanced cancer; however, many cancers are not tested, partly because of tissue limitations. Next-generation sequencing (NGS) liquid biopsies overcome some limitations, but clinical validity is not established and adoption is limited. Herein, clinical bridging studies used pretreatment plasma samples and data from FLAURA (NCT02296125; n = 441) and AURA3 (NCT02151981; n = 450) pivotal studies to demonstrate clinical validity of Guardant360 CDx (NGS LBx) to identify patients with advanced EGFR mutant non-small-cell lung cancer who may benefit from osimertinib.
View Article and Find Full Text PDF